Lara Nonis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lara Nonis has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Léa Sorret
Drug Product Services, Lonza AG, Hochbergerstrasse 60G, 4057 Basel, Switzerland
2 shared publications - Mattias Paulsson
Department of Women's and Children's Health Uppsala University Uppsala Sweden
2 shared publications - Stanley C. Kwok
Dosage Form Design and Development, BioPharmaceutical Development, R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, Gaithersburg MD, 20878, USA
2 shared publications - Balasubramanian Sivakumar
Dosage Form Design and Development, BioPharmaceutical Development, R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, Gaithersburg MD, 20878, USA
1 shared publication - Giorgia De Paoli
School of Health Sciences, University of Dundee, Dundee, United Kingdom
1 shared publication - Giuliana Vozza
Dosage Form Design and Development, BioPharmaceutical Development, R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD 20878, USA
1 shared publication
Latest Publications
- 27 May 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (5)
Safe Handling and Clinical Administration of Antibody Drug Conjugates: Occupational Safety, Material Compatibility, and the Integration of CSTDs into Workflows
Antibody-drug conjugates (ADCs) represent a rapidly expanding class of therapeutics, combining the specificity of monoclonal antibodies with the potency of cytotoxic payloads. Their increasing clinical adoption introduces complex challenges for safe handling, preparation, and administration that extend beyond traditional hazardous drug and monoclonal antibodies - based therapies protocols. These inherent complexities of ADCs necessitate strict controls during handling and administration. This review outlines the current regulatory frameworks and institutional practices guiding ADC's in-use handling and highlights key limitations within these practice systems. We examine current handling practices, including the regulatory and institutional guidance landscape, engineering controls, aseptic compounding environments, and the use of personal protective equipment (PPE), as well as the integration of closed system transfer devices (CSTDs) into clinical and pharmacy workflows. This paper addresses ADC dosing solution stability and administration material compatibility, highlighting risks such as undesired interaction with IV bag materials, tubing, and other administration components while identifying potential gaps in compatibility information availability and accessibility. In addition, the effectiveness of closed-system transfer devices (CSTDs) and their implementation into the clinical workflow are discussed. Finally, we provide recommendations to address the identified gaps to promote safer, more consistent clinical handling practices. Given the complexity of ADC products, the rise of novel ADC constructs, and their expanding application in targeted therapies and alternative administration routes, continued ADC-specific research and regulatory guidance will be essential to achieve safe and effective clinical implementation.
- 27 May 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (5)
Safe Handling and Clinical Administration of Antibody Drug Conjugates: Occupational Safety, Material Compatibility, and the Integration of CSTDs into Workflows
Antibody-drug conjugates (ADCs) represent a rapidly expanding class of therapeutics, combining the specificity of monoclonal antibodies with the potency of cytotoxic payloads. Their increasing clinical adoption introduces complex challenges for safe handling, preparation, and administration that extend beyond traditional hazardous drug and monoclonal antibodies - based therapies protocols. These inherent complexities of ADCs necessitate strict controls during handling and administration. This review outlines the current regulatory frameworks and institutional practices guiding ADC's in-use handling and highlights key limitations within these practice systems. We examine current handling practices, including the regulatory and institutional guidance landscape, engineering controls, aseptic compounding environments, and the use of personal protective equipment (PPE), as well as the integration of closed system transfer devices (CSTDs) into clinical and pharmacy workflows. This paper addresses ADC dosing solution stability and administration material compatibility, highlighting risks such as undesired interaction with IV bag materials, tubing, and other administration components while identifying potential gaps in compatibility information availability and accessibility. In addition, the effectiveness of closed-system transfer devices (CSTDs) and their implementation into the clinical workflow are discussed. Finally, we provide recommendations to address the identified gaps to promote safer, more consistent clinical handling practices. Given the complexity of ADC products, the rise of novel ADC constructs, and their expanding application in targeted therapies and alternative administration routes, continued ADC-specific research and regulatory guidance will be essential to achieve safe and effective clinical implementation.
- Open Access
- 19 March 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (5) , 104253
Multidisciplinary exploratory survey: Initial insights into biologic drug handling and regulatory perspectives among healthcare professionals
- 19 March 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (5) , 104253
Open AccessMultidisciplinary exploratory survey: Initial insights into biologic drug handling and regulatory perspectives among healthcare professionals